🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in India / NCT07167069
Active, not recruiting

India HIV-CervCa Project

NCT07167069 · tracked via the Priya Life Science India tracker
Sponsor
Abramson Cancer Center at Penn Medicine
Phase
Started
2021-02-09
Last updated
2025-09-11

Condition(s) studied

HIV PositiveHIV NegativeCervical Cancer

Investigational drug(s) / intervention(s)

Radiation Therapy

Radiation Therapy: Standard of Care Chemoradiation for Cervical cancer patients in India.

Study summary

The investigators propose to prospectively study the difference in treatment (CTRT) completion and toxicities between HIV positive and HIV negative women in India with locally advanced cervical cancer receiving CTRT.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * patients with newly biopsy proven squamous carcinoma or adenocarcinoma of the uterine cervix, FIGO stage IB2-IIIB in whom curative CTRT is planned * Karnofsky performance status ≥ 70 * Patients with lower paraortic lymph nodes (below the level of L2 vertebra) * patients diagnosed with cervical cancer whom also HIV positive or HIV negative Exclusion Criteria: * patients with active tuberculosis

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tata Memorial Hospital Mumbai Maharashtra
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07167069 on ClinicalTrials.gov ↗ ← All trials in India